Literature DB >> 8958911

Interleukin 12: cellular and molecular immunology of an important regulatory cytokine. Introduction.

M T Lotze1.   

Abstract

Mesh:

Substances:

Year:  1996        PMID: 8958911     DOI: 10.1111/j.1749-6632.1996.tb52649.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


× No keyword cloud information.
  5 in total

1.  Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial.

Authors:  E Antonio Chiocca; John S Yu; Rimas V Lukas; Isaac H Solomon; Keith L Ligon; Hiroshi Nakashima; Daniel A Triggs; David A Reardon; Patrick Wen; Brittany M Stopa; Ajay Naik; Jeremy Rudnick; Jethro L Hu; Priya Kumthekar; Bakhtiar Yamini; Jill Y Buck; Nathan Demars; John A Barrett; Arnold B Gelb; John Zhou; Francois Lebel; Laurence J N Cooper
Journal:  Sci Transl Med       Date:  2019-08-14       Impact factor: 17.956

2.  Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial.

Authors:  E Antonio Chiocca; Arnold B Gelb; Clark C Chen; Ganesh Rao; David A Reardon; Patrick Y Wen; Wenya Linda Bi; Pierpaolo Peruzzi; Christina Amidei; Dan Triggs; Leah Seften; Grace Park; James Grant; Kyla Truman; Jill Y Buck; Nira Hadar; Nathan Demars; John Miao; Taylor Estupinan; John Loewy; Kamal Chadha; Joseph Tringali; Laurence Cooper; Rimas V Lukas
Journal:  Neuro Oncol       Date:  2022-06-01       Impact factor: 13.029

Review 3.  Next Steps for Immunotherapy in Glioblastoma.

Authors:  Toni Q Cao; Derek A Wainwright; Catalina Lee-Chang; Jason Miska; Adam M Sonabend; Amy B Heimberger; Rimas V Lukas
Journal:  Cancers (Basel)       Date:  2022-08-20       Impact factor: 6.575

4.  Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression.

Authors:  B S Diniz; E Sibille; Y Ding; G Tseng; H J Aizenstein; F Lotrich; J T Becker; O L Lopez; M T Lotze; W E Klunk; C F Reynolds; M A Butters
Journal:  Mol Psychiatry       Date:  2014-08-05       Impact factor: 15.992

5.  Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects.

Authors:  Mamata S Gokhale; Vladimir Vainstein; Jamie Tom; Simmy Thomas; Chris E Lawrence; Zoya Gluzman-Poltorak; Nicholas Siebers; Lena A Basile
Journal:  Exp Hematol Oncol       Date:  2014-04-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.